Ganzhou Hospital of Guangdong Provincial People's Hospital, Ganzhou Municipal Hospital, No. 49 Da Gong Street, Ganzhou, 341000, China.
Gannan Medical University, No. 1 Medical College Road, Ganzhou, 341000, China.
World J Surg Oncol. 2023 Jun 1;21(1):165. doi: 10.1186/s12957-023-03055-0.
At present, pancreatic cancer (PC) has a high morbidity and mortality rate and a poor prognosis. The aim of this article was to study the efficacy and safety of apatinib combined with radiotherapy in the treatment of advanced PC.
The PubMed, Cochrane Library, Embase, Wanfang, CNKI, VIP, and CBM databases were searched by computer to identify studies on the application of apatinib in patients with advanced PC. The patients in the included study were divided into an observation group (apatinib combined with radiotherapy) and a control group (radiotherapy only), and meta-analysis was performed for each outcome with Revman 5.4 software. This study was successfully registered on the PROSPERO website, and the registration number is CRD: 42,022,384,056 (available at https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=384056 ).
A total of 7 randomized controlled trials (RCTs) with 428 patients were included, including 215 in the observation group and 213 in the control group. Compared with the control group, the observation group showed a greater objective response rate [OR = 3.26, 95% CI (2.18, 4.87), P < 0.0001], disease control rate [OR = 5.04, 95% CI (3.12, 8.12), P < 0.0001], complete response rate [OR = 3.87, 95% CI (1.51, 9.88), P = 0.005], and partial response rate [OR = 2.43, 95% CI (1.63, 3.61), P < 0.001], The 1-year survival rate [OR = 2.39, 95% CI (1.15, 4.96), P < 0.05], 2-year survival rate [OR = 2.41, 95% CI (1.03, 5.61), P < 0.05], progression-free survival time [MD = 1.17, 95% CI (0.37, 1.96), P < 0.05], overall survival time [MD = 1.47, 95% CI (0.13, 2.80), P < 0.05], while the stability rate [OR = 1.14, 95% CI (0.72, 1.81), P = 0.58] and various complications were not significantly different between the two groups.
Apatinib combined with radiotherapy was more effective than radiotherapy alone in the treatment of advanced pancreatic cancer (PC), and apatinib had acceptable safety. However, since our study was limited by the quantity and quality of the included studies, we look forward to more large-sample, multicentre, and high-quality RCTs in the future to verify the conclusions.
目前，胰腺癌（PC）的发病率和死亡率较高，预后较差。本文旨在研究阿帕替尼联合放疗治疗晚期 PC 的疗效和安全性。
计算机检索 PubMed、Cochrane Library、Embase、万方、CNKI、VIP 和 CBM 数据库，查找阿帕替尼在晚期 PC 患者中应用的相关研究。将纳入研究的患者分为观察组（阿帕替尼联合放疗）和对照组（单纯放疗），采用 Revman 5.4 软件对各结局进行 meta 分析。本研究已成功在 PROSPERO 网站注册，注册号为 CRD:42,022,384,056（可在 https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=384056 获得）。
共纳入 7 项随机对照试验（RCT），共计 428 例患者，观察组 215 例，对照组 213 例。与对照组相比，观察组客观缓解率[OR=3.26，95%CI（2.18，4.87），P<0.0001]、疾病控制率[OR=5.04，95%CI（3.12，8.12），P<0.0001]、完全缓解率[OR=3.87，95%CI（1.51，9.88），P=0.005]、部分缓解率[OR=2.43，95%CI（1.63，3.61），P<0.001]更高，1 年生存率[OR=2.39，95%CI（1.15，4.96），P<0.05]、2 年生存率[OR=2.41，95%CI（1.03，5.61），P<0.05]、无进展生存期[MD=1.17，95%CI（0.37，1.96），P<0.05]、总生存期[MD=1.47，95%CI（0.13，2.80），P<0.05]更长，而两组的稳定率[OR=1.14，95%CI（0.72，1.81），P=0.58]和各种并发症发生率无显著差异。
阿帕替尼联合放疗治疗晚期胰腺癌（PC）的疗效优于单纯放疗，且阿帕替尼具有可接受的安全性。但由于本研究受纳入研究的数量和质量限制，我们期待未来有更多大样本、多中心、高质量的 RCT 来验证这些结论。
